Jaundice is a critical global health issue among newborns
Jaundice is the #1 reason why newborns are readmitted to hospitals worldwide. About 3 in 5 children have some degree of jaundice. For approximately 18% of babies, the condition is severe and requires treatment. Severe jaundice, when left untreated or ineffectively treated, can lead to severe brain damage, a condition called kernicterus, or death.
Millions of babies are not receiving the effective care they need
With experts at Stanford University School of Medicine, we estimate that every year, over 6 million babies with severe jaundice are not receiving adequate treatment.1
1 “BK Cline, R Vilms, K. McGraw, HH Lou, KM Donaldson, VK Bhutani. Global Burden and Unmet Need for Hyperbilirubinemia Treatment. Poster session presented at: Pediatric Academic Society; 2011 April 30-May 3; Denver, CO.”
Current treatment devices are costly to purchase and maintain
In studies of medical facilities in India and Nigeria, D-Rev and Stanford found that 95% of devices evaluated in low-income hospitals and clinics did not meet American Academy of Pediatrics standards for intensive phototherapy.2,3 Maintenance was a key limitation in delivery of treatment: approximately 1 in 3 phototherapy devices had at least one bulb burned out or missing. Compact florescent bulbs, commonly used in phototherapy devices, cost approximately $15 per bulb to replace and last approximately four months. Many hospitals have trouble sourcing these bulbs and, with devices using an average of six bulbs each, they simply can’t afford to replace them as needed.
2 Cline, Benjamin K., et al. “Phototherapy device effectiveness in Nigeria: irradiance assessment and potential for improvement.” *Journal of tropical pediatrics* (2013): fmt027.
3 Cline BK, Daly RE, Donaldson KM, et al: Evaluation of Phototherapy Device Efficacy in Resource-Limited Nurseries. Pediatric Academic Societies. Abstract 1496:535, 2010. Available at:https://www.abstracts2view.com/pas/view. Accessed March 17, 2011
1 in 3 devices had at least one bulb burnt out or missing
We are starting where the need is most critical
We learned from our fieldwork and due diligence that urban and district hospitals rarely have effective phototherapy—in fact only 5% in our target areas. To reach the most newborns, Brilliance is designed for hospitals where the sickest children are treated. district sized hospitals with NICUs who treat the sickest children.
• Peak wavelength 450–465nm
• Uniform intensity >45µW/cm²/nm
• Effective treatment area >1300cm²
Patent-pending technology to ensure that light intensity from blue LEDs is consistent across the treatment footprint at any angle of head-tilt. SmartTiltTM ensures that Brilliance Pro works effectively at any position with other newborn care equipment.
Brilliance Pro only
Brilliance consumes less than half the electricity of CFLs.
Brilliance is designed for versatility of use. Brilliance can be integrated with other critical medical equipment such as infant warmers, incubators, and nearly any variety of bassinet.
Brilliance LEDs last 60x longer than compact fluorescent lamps (CFL) commonly used in phototherapy devices. With Brilliance, hospitals can save over $240 USD per year on costly bulb replacements. Also, Brilliance can withstand a wide range of power fluctuations without changes in device performance.
Made in India, designed in USA
Compare Brilliance Models
Brilliance Proplus light meter
D-Rev’s most groundbreaking product to-date. With sophisticated programming and advanced design, Brilliance Pro has an integrated light meter, expanded functionality, and a sleek look to work better in the NICU.
The original design of Brilliance Classic combines world-class performance with the most affordable price for a phototherapy unit to treat severe jaundice in the most resource-limited hospitals.
Designed with Phoenix Medical Systems in India, Brilliance Underside works in tandem with both Classic and Pro when double-sided phototherapy is needed to accelerate treatment.
Integrated Light Meter (available)
>45µW/cm²/nmat recommended treatment distance of 35cm
>45µW/cm²/nmat recommended treatment distance of 35cm
>30µW/cm²/nmat fixed treatment distance
High & Low Settings
Peak Wave-length of Light
Tilting LED Panel
Tilts with bassinet
Total Machine Run Timer
Product Launch Date
Base Retail Price w/ 1-year warranty
Backlit LCD Screen
Observation Lights (available)
Passive Cooling (no fan)
D-Rev research and collaborations
The Need to Implement Effective Phototherapy in Resource-Constrained Settings
Device Effectiveness in Nigeria: Current Irradiance Levels and Simple Strategies for Improvement
A Global Strategy to Screen and Prevent the Need for the Exchange Transfusion
In late 2010, D-Rev licensed Brilliance Classic to Phoenix Medical Systems in Chennai, India. Phoenix is the largest manufacturer and seller of quality neonatal care equipment in India with 70% of the market share of compact florescent bulb phototherapy devices in the country. Brilliance Classic was released on the market in November 2012. Phoenix is currently manufacturing, distributing, and selling Brilliance throughout India and much of the rest of the world.
The licensing agreement is structured to incentivize sales to public hospitals in India and low-income countries. Specifically, the target markets are countries categorized by the United Nations Human Development Index as low or medium resource-limited. Through dialogue with Indian medical professionals, D-Rev and Phoenix have agreed to cap the selling price of Brilliance units based on the cost of goods sold to ensure affordability in emerging and undercapitalized markets.
• Brilliance Classic – $400 USD
• Brilliance Pro – $400 USD
• Brilliance Underside – $400 USD
Established in 1989, Phoenix is committed to quality, technology, and innovation with an excellent in-house research and development team. Phoenix products are trusted worldwide and used in almost all premier hospital and medical institutions in India. Phoenix has ISO certifications and pursues international standards in ensuring the highest safety of all its products.